Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


JP Morgan Notebook Day One: Pfizer/Allergan, Celgene, Gilead, Teva And More

This article was originally published in Scrip

Executive Summary

Pfizer Inc. chairman and CEO Ian Read and Allergan PLC president and CEO Brent Saunders noted in a Jan. 11 interview with Scrip during the 34th Annual JP Morgan Healthcare Conference in San Francisco that investors' biggest concern about the pending $160bn merger of the two companies do not revolve around whether or not the combined entity will continue early-stage research and development or whether more dealmaking is on the horizon.

You may also be interested in...

Roivant's Ramaswamy Woos Celgene's Fouse To Lead Dermavant

The former Celgene president has joined Roivant subsidiary Dermavant with big ambitions to turn the start up into a dermatology leader. Ramaswamy and Fouse talk about next steps for the start up.

Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease

Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.

Moderna CEO Hearing Highlights Dissatisfaction With Patient Assistance Programs

There was bipartisan agreement that Moderna need to ensure that its patient assistance program will be easily accessible for under- and uninsured patients once the US switches to a commercial market for COVID vaccines – a sign of broader frustration with industry copay support initiatives.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts